Clinical Use of Coherex FlatStent EF PFO Closure System Covered at TCT 2009

 
September 18, 2009
The FlatStent EF

September 18, 2009 – Coherex Medical Inc. will host a lunch symposium titled “In-Tunnel PFO Closure: Treating the Tunnel Using the Coherex FlatStent EF PFO Closure System,” on Tuesday, Sept. 22, during TCT 2009.

The Coherex lunch symposium will be held from noon to 1 p.m. in room 121 of the Moscone Center in San Francisco. The symposium features brief lectures and commentary from leading interventional cardiologists who have vast experience in structural heart disease and closing patent foramen ovale (PFO), a common heart defect.

Mark Reisman, M.D., director of the cardiac catheterization lab at Swedish Heart & Vascular Institute in Seattle, will serve as moderator. Presenters during the symposium, and their respective topics, include:

• Martin Leon, M.D., associate director of the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia Medical Center, professor of medicine at Columbia University, and chairman emeritus of CRF, will discuss “Introduction: ‘In-Tunnel’ PFO Closure has Arrived!”

• Brian Whisenant, M.D., Utah Heart Clinic and Coherex Medical cofounder, will present “How the Coherex FlatStent PFO Closure System Works.”

• Ziyad Hijazi, M.D., director, Rush Center for Congenital and Structural Heart Disease, section chief, pediatric cardiology, professor of pediatrics and internal medicine, Rush University Medical Center, Chicago, will discuss “Tunnel Morphology. It’s Important, But Not Why You Think!”

• Horst Sievert, M.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen, and the Department of Internal Medicine, Cardiology and Vascular Medicine of the Sankt Katharinen Hospital, Frankfurt, Germany, will discuss “Clinical Results and Lessons from the Coherex-EU Clinical Trial.”

• Peter Ruygrok, M.D., Auckland Heart Group, clinical director of the Green Lane Cardiovascular Service at Auckland City Hospital, New Zealand, will discuss “Keys to Success in FlatStent EF Deployment.”

• David Muller, M.D., associate professor, director of interventional cardiology, St. Vincent’s Hospital, Sydney, Australia, will discuss “New Device – Short Learning Curve. My Experience Learning the Coherex FlatStent EF Method.”

Following the presentations, Dr. Reisman will lead a short question and answer session with the symposium presenters.

Coherex announced in June that the Coherex FlatStent EF was the first “in-tunnel” device to receive CE mark clearance for closing PFO heart defects, a condition found in approximately 20 percent of the worldwide population.

For more information: www.coherex.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.